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Aim: Evaluate the effect of lipopenic and hypotensive treatment on homocysteine levels.
Methods: We recruited 145 type 2 diabetics and 130 control subjects. Thirty-seven diabetics had 
no complications, 54 had microvascular complications and 54 had macrovascular complications. 
We determined the parameters homocysteine of lipid, vitamin B12, triglycerides, and folates 
for all subjects. Associated treatments used one or more of the following drugs, statin, fibrate, 
angiotensin-converting enzyme inhibitor and beta-blockers.
Results: Hyperhomocysteinemia was present in 35.6% of patients. Diabetics had elevated serum 
levels of triglycerides (P  0.001), homocysteine (P  0.01), folates (P  0.01) and vitamin B12 
(P  0.001). A strong association was found between type 2 diabetes and hyperhomocysteinemia 
(P  0.001). Diabetics with associated treatment had elevated homocysteine, vitamin B12 
and folate levels when compared to diabetes-free controls. For diabetics with macrovascular 
complications, we found significant differences in homocysteine (P = 0.010) and folate 
(P = 0.014) between those taking associated drugs and those who did not. For diabetics with 
microvascular complications, a significant difference was found in folate only (P = 0.012).
Conclusion: Drugs used for hypertension and hyperlipidemia may have an effect on 
homocysteine levels, for this reason the interaction between drug action and homocysteine 
levels should be taken into consideration.
Keywords: type 2 diabetes, complications, homocysteine, hypolipemiant drug, hypotensive 
drug
Introduction
Type 2 diabetes mellitus constitutes a major public health problem that leads to the 
development of various chronic complications. Macrovascular disease represents the 
main cause of mortality in patients with diabetes. In fact, the damage of the endothelial 
wall plays an important role in the development of diabetic complications. Other 
multiple risk factors are considered in the assessment of chronic diabetic complications 
such as hyperglycemia, dyslipidemia, genetic factors, and oxidative stress.1 Recently 
there has been a focus on homocysteine (Hcy) as a new risk factor implicated in 
atherogenesis, in particular for diabetes. Hcy is a sulfhydryl amino acid involved in 
the metabolism of the essential amino acid, methionine. High levels of Hcy are consid-
ered to be related to many diseases and especially to cardiovascular complications.2,3 
Elevated Hcy levels may contribute to the cardiovascular disease risk of type 2 diabetic 
patients. Hcy concentrations can change due to multiple factors such as vitamin levels, 
when reduced may cause hyperhomocysteinemia,4,5 and mutations in genes coding for 
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enzymes involved in Hcy metabolism. Other factors that may 
have an effect on Hcy levels include medicines (eg, theophil-
line, methotrexate)6 and such diseases as hypothyroidism, 
kidney pathologies, cancers, and others.7
In the present study we evaluated the effect of the 
hypolipemiant and hypotensive treatment on homocysteine 
levels in type 2 diabetes.
Material and methods
study group
This case control study was performed in a group of 
275 participants (145 type 2 diabetes and 130 control 
subjects). Type 2 diabetic patients were hospitalized in the 
Department of Endocrinology at the Military Hospital in 
Tunis. The recruit, was followed for 6 months. Patients 
with hypothyroidism or chronic renal disease were not 
included in this study. A questionnaire was performed for 
all participants and the information recorded included: 
personal, anthropometric, and lifestyle data (including 
smoking habits); clinical history; and data relevant to 
microvascular (retinopathy, blindness, nephropathy, and foot 
ulcers); and macrovascular complications (coronary heart 
disease [CHD] ed group, cerebral thromboembolism, and 
peripheral amputations); and laboratory data. Treatment for 
diabetes was defined as requiring drug treatment at admis-
sion (eg, insulin injection, or oral hypoglycemic agents). 
Treatments used for hyperlipidemia and hypertension were 
classified as, statin fibrate, inhibitor enzyme conversion, and 
beta-blockers. Associated treatment is defined as one or more 
of the cited drugs which were used by patients and noted at 
their admission, ie, patients taking drugs for prevention or 
as needed treatment. We classified diabetics into subgroups 
according to the presence or absence of vascular complica-
tions. Thirty-seven diabetics had no complications, 54 had 
microvascular complications, and 54 had macrovascular 
complications. The numbers of patients with associated 
treatment were 59 with diabetes, 35 were diabetics with 
macrovascular complications, and 26 were diabetics with 
microvascular complications.
The control group consisted of 130 selected subjects 
from various medical and paramedical individuals within 
the hospital. Subjects completed a large questionnaire before 
their participation. Only subjects without any complications 
or disease, which might influence Hcy levels and were not 
using any prescribed treatments were included in the study. 
None of the participants took any vitamin supplementation. 
All subjects accepted by the study signed a consent form 
provided by the hospital ethics committee.
Laboratory analysis
Blood was withdrawn from subjects after an overnight fast. 
The plasma was separated within one hour of sampling by 
centrifugation (3500 rpm/minute for 15 minutes). Aliquots 
for the determination of Hcy, folates (Fol), vitamin B12 
(vitB12) were stored at −20°C until analysis. Lipids were 
determined on the same day of collection. Total cholesterol 
(TC), triglycerides (TG) and high-density lipoprotein cho-
lesterol (HDL-C) were measured by using a colorimetric 
enzymatic method in a Technicon automatic analyzer 
(RA-1000; Dade Behring, Los Angeles, CA). Total choles-
terol was determined by end point colorimetric enzymatic 
method with cholesterol oxidase and peroxidase (Bioméri-
eux, Marcy l’Etoile, France). HDL-C was determined by 
the same method after selective precipitation of low-density 
lipoprotein (LDL) and very low-density lipoprotein (VLDL). 
Triglycerides were determined by an end point colorimetric 
enzymatic method with lipase, glycerokinase, glycerophos-
phate oxidase and peroxidase (Biomérieux). LDL-C was 
calculated by Friedwald’s formula:
LDL-C = TC – (HDL-C + TG/2.18) for TG  4.5 mM/L.
The blood for measuring total homocysteine (tHcy) was 
collected in tubes containing EDTA and were kept on ice 
until centrifuged (3500 rpm/minute for 15 minutes). The 
plasma was stored at −20°C until assayed. The concentrations 
of tHcy in plasma were evaluated by using an automatic 
analyzer (Immulite 1000 DPC; Siemens Medical Solutions, 
Los Angeles, CA) based on a competitive immunoassay. 
The Hcy assay involves a preliminary manual pretreatment 
step; Hcy is released from its binding proteins and con-
verted to S-adenosyl-homocysteine (SAH) by an off-line 30 
minute incubation at 37°C in the presence of S-adenosyl-L-
homocysteine hydrolase and dithiothreitol (DTT). Vitamin 
B12 and folates were measured by an immunometric method 
using chemiluminescent markers (Immulite 2000 DPC; Sie-
mens Medical Solutions).
statistical analysis
Results were statistically analyzed by SPSS software (v. 10.0 
for Windows; SPSS Inc., Chicago, IL) Continuous variables 
are presented as means ± standard deviation (SD), and qualita-
tive variables as relative frequencies. Kolmogorov–Smirnov 
test for the normality of different parameters showed a normal 
distribution only for some parameters. We used a t-test to 
compare quantitative variables and a Chi-square test to com-
pare qualitative variables. The odds ratio was used to assess 
the relative risk with a confidence interval at 95%. Correlation Vascular Health and Risk Management 2010:6 329
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between variables was determined by Spearman test. The 
differences were significant if P value was less than 0.05.
Results
Characteristics of the study population are shown in Table 1. 
Diabetic patients had elevated TC, LDL-C, TG, tHcy, Fol and 
vitB12 with significant differences in TG (P  0.001), tHcy 
(P  0.01), Fol (P  0.01) and VitB12 (P  0.001) com-
pared to controls. Significant negative correlation was found 
between Hcy and folates (r = −0,23; P  0.01 ) (Table 1).
Hyperhomocysteinemia (Hcy  15 µM/L) was present in 
35.6% of patients. The mean Hcy was significantly higher in 
type 2 diabetic patients than in the control group (Table 1). 
Men had significantly higher Hcy as compared to women 
only in the control group (P  0.05 ) (Table 2).
A significant difference between patients taking 
associated treatment and those who did not was noted Fol 
(P  0.01 ) (Table 3).
In order to evaluate the association between hyperhomo-
cysteinemia and type 2 diabetes a Chi-square test was per-
formed; in this we found a strong association (P  0.001 ).
When we subdivided patients according to the type of 
complication we found that diabetics with macrovascular 
complication had elevated tHcy levels (15.06 ± 7.94 µM/L) 
when compared to those with microvascular complications 
(13.90 ± 7.53 µM/L) and those with no complications 
(12.64 ± 6.55 µmol/L). The odds ratio (OR) was 2.5 (with 
a 95% confidence interval [CI]: 0.94–6.61; P = 0.05) and 
1.69, (95% CI: 0.62–4.59; P = 0.21) for macrovascular and 
microvascular complications respectively.
We found that diabetics treated with insulin (n = 39) 
had elevated Hcy compared to those not treated with insulin 
(n = 80) (16.17 ± 8.45 µM/L versus 12.57 ± 6.46 µM/L; 
P  0.05).
In diabetics with macrovascular complications we found 
significant differences in Hcy and Fol levels between diabetics 
taking associated drugs and those who did not. For diabetics 
with microvascular complications, we only found a significant 
difference in Fol levels (Table 4).
Discussion
Hyperhomocysteinemia is now established as a risk factor 
for cardiovascular disease, especially in diabetic patients. In 
our study 35.6% of patients had hyperhomocysteinemia, with 
higher Hcy levels in men. Sadeghian and colleagues8 found 
that plasma tHcy levels in men were significantly higher 
than in women and that the male gender was an effective 
factor in Hcy plasma levels. Influence of tobacco smoking 
on Hcy levels has been reported in literature. Such studies 
demonstrated a positive effect of tobacco on Hcy levels.9,10 
In our study we did not find any significant difference in 
Hcy levels between smokers and nonsmokers, and neither in 
diabetics nor in control subjects despite elevated Hcy levels 
Table 1 clinical and biological characteristics of the study group
  Control subjects Type 2 diabetics P
number  
(men/women)
130 (74/56) 145 (75/70) –
Age (years) 50.14 ± 7.99 56.36 ± 11.57 ns
BMi (kg/m2) 25.63 ± 3.63 28.61 ± 5.12 0.001
Tobacco (%) 33.1 38.1 ns
Total cholesterol 
(mM/L)
4.66 ± 1.06 4.93 ± 1.17 ns
LDL-c (mM/L) 3.08 ± 0.95 3.13 ± 0.98 ns
HDL-c (mM/L) 1.13 ± 0.30 1.12 ± 0.29 ns
Tg (mM/L) 1.04 ± 0.64 1.48 ± 0.93 0.001
Hcy (µML) 11.65 ± 4.73 14.26 ± 7.54 0.01
Fol (ng/mL) 6.52 ± 4.45 8.98 ± 7.23 0.01
VitB12 (pg/mL) 267.75 ± 112.25 375.08 ± 262.30 0.001
Abbreviations: BMi, body mass index; LDL-c, low-density lipoprotein cholesterol; 
HDL-c, high-density lipoprotein cholesterol; Tg, triglycerides; Hcy, homocysteine; 
Fol, folate; VitB12, vitamin B12; NS, nonsignificant.
Table 2 comparison of homocysteine levels between men and 
women
Number Homocysteine (µmol/L) P
Men
control 74 12.41 ± 4.53
case 75 14.63 ± 7.72 0.037
ns* 0.035§
Women
control 56 10.63 ± 4.84
case 70 13.84 ± 7.36 0.007
Note: comparison of men to women *in the study group, §in the control group. 
Abbreviations: NS, not significant.
Table 3 Effect of the associated treatment on homocysteine levels 
in diabetic patients
  
 
 
Type 2 diabetics 
with associated 
treatment  
G1(59)
Type 2 diabetics  
without associated  
treatment  
G2 (76)
P 
 
 
Hcy (µM/L) 15.22 ± 7.52 13.02 ± 7.43 0.094
Folates (ng/mL) 7.55 ± 6.04 10.88 ± 8.22 0.009
VitB12 (pg/mL) 412.80 ± 270.54 324.57 ± 244.16 0.057
Note: Associated treatment is one or more of the following: statin, fibrate, 
inhibitor enzyme conversion, and beta-blockers.
Abbreviations: Hcy, homocysteine; Fol, folate; VitB12, vitamin B12.Vascular Health and Risk Management 2010:6 330
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in smokers. In the present study we found elevated tHcy 
levels in diabetic patients and that there was an association 
between hyperhomocysteinemia and type 2 diabetes. This 
result is inline with those of other case control studies.11,12 
Such elevated tHcy levels have been shown to be associated 
to cardiovascular disease (CVD) in most studies. Hoogeveen 
and colleagues13,14 reported an increased mortality due to 
CVD in diabetic patients with elevated tHcy concentrations. 
In a recently published study, by this laboratory we found that 
hyperhomocysteinemia is an independent risk factor for CVD 
incidence in diabetic patients.15 In the present study we found 
that diabetics with macrovascular complications had elevated 
tHcy levels when compared to those with microvascular 
complications. Buysschaert and colleagues16 found a higher 
incidence of macroangiopathy and nephropathy in a group of 
diabetics with hyperhomocysteinemia. Indeed such studies 
have reported the effect of diabetes treatment on the tHcy 
levels. Otmane and colleagues17 found that tHcy levels were 
higher in patients treated with sulfonamide than those treated 
with metformin. These results are in contrast with those found 
by Sahin and colleagues18 who demonstrated that metformin 
in type 2 diabetes increases Hcy levels, whereas rosiglitazone 
decreases Hcy level in the same time period. In a study by 
Derosa and colleagues19 glimepiride was shown to have had 
a lowering effect on tHcy levels whereas metformin did not.20 
These drugs exacerbated vitamin B12 and folate deficiency, 
which is not the case in our study, as diabetic patients had 
elevated vitamin B12 and folate levels. This can be explained 
in part that elevated Hcy levels in diabetic patients may 
be due to an unknown factor in our study, possibly in the 
treatment the diabetics received. Some authors suggest that 
lower folic acid concentrations observed in diabetic patients 
may be explained in terms of hyperglycemia increasing solu-
ble vitamin secretion.21 Evidence from another study suggests 
that insulin and sulfonylurea treatment do not alter plasma 
tHcy.22 Rudy and colleagues23 did not found any significant 
difference between diabetic patients who were administered 
insulin and those who were administered oral agents. In our 
study, we found that diabetics treated with insulin had elevated 
tHcy levels when compared to those not treated with insulin, 
(independent of oral agents). Indeed insulin has important 
effects on protein and amino acid metabolism. However, its 
effect on Hcy metabolism has not been well studied. During 
a hyperinsulinemic euglycemic clamp, plasma tHcy levels 
fell by approximately 20% in normal subjects but did not do 
so in insulin resistant patients with type 2 diabetes.24 These 
data suggest that plasma homocysteine concentrations are 
regulated by acute hyperinsulinemia in normal subjects but 
not in insulin-resistant diabetic patients.
Diabetics with macrovascular complications in our study 
had the elevated tHcy levels and that those with associated 
treatment (drugs for CVD prevention, hypertension 
or dyslipidemia) also had elevated tHcy levels when 
compared to those without associated treatment. In fact, 
beyond their effect on lipids certain drugs such as fenofibrate 
may affect other markers of CVD risk.25 The elevation of tHcy 
levels after fenofibrate treatment may show a modest effect 
of fenofibrate on the reduction of CVD risk.26 Mayer and 
colleagues27 demonstrated that fenofibrate decreases LDL-C 
but in contrast to fluvastatin has no significant antioxidative 
and endothelium-protective potential, probably due to a 
concomitant increase of tHcy. Miltiadous and colleagues28 
demonstrated statins have no effect on Hcy levels, and that 
their antiatherogenic properties (other than their cholesterol 
lowering effect) are not due to any change in Hcy plasma levels. 
However, in a recent study by Lin and colleagues29 statins 
could directly reduce Hcy-induced endothelial mononuclear 
cell (MNC) adhesion via vascular cell adhesion molecule-1 
(VCAM-1) inhibition, suggesting its potential implication in 
Hcy-related atherosclerosis disease. In another study, statins 
may be an appropriate management option for polycystic ovary 
syndrome patients with hyperhomocysteinemia.30
It is important to determine whether lowering Hcy 
levels will prevent the onset of vascular disease in diabetic 
patients. Vitamin therapy may be necessary to correct 
hyperhomocysteinemia in many patients. In fact, several 
investigators have reported the role of vitamin therapy in 
lowering elevated tHcy concentrations.31,32 However, the 
role of vitamin therapy in decreasing the risk of vascular 
Table 4 comparison between diabetics with associated treatment 
and those without in macro- and microvascular complicated 
subgroups
  SG1 SG2 P
Macrovascular  
complications
(35) (15)
Hcy (µM/L) 16.91 ± 7.56 10.84 ± 6.76 0.010
Fol (ng/mL) 8.89 ± 6.81 15.99 ± 12.01 0.014
VitB12 (pg/mL) 467.26 ± 255.45 345.07 ± 268.16 ns
Microvascular  
complications
(26) (17)
Hcy (µmol/L) 14.56 ± 7.77 12.69 ± 7.66 ns
Fol (ng/mL) 5.48 ± 4.83 10.19 ± 5.48 0.012
VitB12 (pg/mL) 349.92 ± 296.44 347.37 ± 225.55 ns
Notes: sg 1, subgroup of diabetes with associated treatment; sg 2, subgroup without 
associated treatment.
Abbreviations: ns, not significant; Hcy, homocysteine; Fol, folate; VitB12, 
vitamin B12.Vascular Health and Risk Management 2010:6 331
Homocysteine variance in type 2 diabetics Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
events is still unclear. A recent Vitamin Intervention for 
Stroke Prevention study failed to show any clinical effect 
on stroke prevention,33 whereas Bazzano and colleagues34 
in a recent clinical study demonstrated that folic acid 
supplementation may reduce congenital heart defects in 
offspring. Although there is doubt about the role of vita-
min therapy and the effect of drugs for the treatment of 
vascular disease on Hcy levels, we should not discontinue 
these treatments.
One of the limitations of our study was the small sample of 
patients taking associated treatment, because of this we did not 
sub-classify them according to individual drug treatment.
In conclusion, we can conclude that drugs used for 
hypertension and hyperlipidemia may have an effect 
on homocysteine levels which in turn could precipitate 
the proliferation of chronic complications, especially 
macrovascular ones. The duration of the drugs used may also 
have an effect on homocysteine and that is why we should take 
in consideration such interactions; to determine the precise 
action and metabolism by which homocysteine has such an 
effect on vascular diseases.
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